ICS/LAMA/LABA triple inhaler
Mometasone with glycopyrronium and indacaterol
Brand names: Enerzair Breezhaler
Adult dose
Dose: 1 inhalation OD
Route: Inhaled
Frequency: OD
Clinical pearls
- Severe asthma not controlled on ICS/LABA; not licensed for COPD
- Once-daily, single device
Contraindications
- Severe milk-protein allergy
- Hypersensitivity
Side effects
- Oral candidiasis
- UTI
- Tachycardia
- Tremor
- Dry mouth
- Pneumonia (COPD class effect)
Interactions
- β-blockers
- QT-prolonging drugs
- Strong CYP3A4 inhibitors
- Other antimuscarinics
Reference: BNF; NICE NG80; https://bnf.nice.org.uk/drugs/mometasone-furoate-with-glycopyrronium-bromide-and-indacaterol/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024